Jens Voortman

2.0k total citations
41 papers, 890 citations indexed

About

Jens Voortman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jens Voortman has authored 41 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Jens Voortman's work include Cancer Immunotherapy and Biomarkers (13 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Urinary and Genital Oncology Studies (7 papers). Jens Voortman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Urinary and Genital Oncology Studies (7 papers). Jens Voortman collaborates with scholars based in Netherlands, United States and United Kingdom. Jens Voortman's co-authors include Giuseppe Giaccone, Frank A.E. Kruyt, Elizabeth R. Gilbert, Fedor Berditchevski, Elena Odintsova, Tatiana P. Resende, Mohamed Hassan, Agnieszka Chęcińska, Henk M.W. Verheul and Tineke E. Buffart and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jens Voortman

40 papers receiving 872 citations

Peers

Jens Voortman

ONCOL

PRM

IMMUN

Marta A. Crispens United States

Yun-Fei Xia China

Ewan Brown United Kingdom

Jurjees Hasan United Kingdom

Hamilto Yamamoto Brazil

Joo Han Lim South Korea

Clara Klerk Netherlands

Jan Kornafel Poland

Jianguo Sun China

Marta A. Crispens United States

Jens Voortman

568 ×1.3

498 ×1.4

ONCOL

185 ×1.2

PRM

296 ×2.0

244 ×2.2

IMMUN

Citations per year, relative to Jens Voortman Jens Voortman (= 1×) peers Marta A. Crispens

Countries citing papers authored by Jens Voortman

Since Specialization

Citations

This map shows the geographic impact of Jens Voortman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Voortman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Voortman more than expected).

Fields of papers citing papers by Jens Voortman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Voortman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Voortman. The network helps show where Jens Voortman may publish in the future.

Co-authorship network of co-authors of Jens Voortman

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Voortman. A scholar is included among the top collaborators of Jens Voortman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Voortman. Jens Voortman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robbrecht, Debbie, John W.M. Martens, Maureen J.B. Aarts, et al.. (2025). Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis. European Urology Oncology. 9(1). 7–11. 1 indexed citations

Mehra, Niven, Jens Voortman, David R. Wise, et al.. (2024). Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). TPS2672–TPS2672. 4 indexed citations

Robbrecht, Debbie, Alberto Gil-Jimenez, Hayri E. Balcıoğlu, et al.. (2024). Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer. Nature Communications. 15(1). 1349–1349. 6 indexed citations

Voortman, Jens. (2024). No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma. The Lancet Oncology. 25(5). 533–534.

Goldman, Jonathan W., Sarina A. Piha‐Paul, Brendan D. Curti, et al.. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(17). 3709–3719. 19 indexed citations

Robbrecht, Debbie, Ronald de Wit, Vanja de Weerd, et al.. (2022). Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. Molecular Oncology. 16(10). 2086–2097. 14 indexed citations

Robbrecht, Debbie, Mandy van Brakel, Joost L. Boormans, et al.. (2022). A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer. Cancer Immunology Immunotherapy. 72(3). 759–767. 9 indexed citations

Reijke, Theo M. de, R. Jeroen A. van Moorselaar, Mila Donker, et al.. (2022). Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. European Urology. 82(5). 518–526. 18 indexed citations

Riet, Job van, Michiel S. van der Heijden, Jens Voortman, et al.. (2022). Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. European Urology. 81(4). 331–336. 22 indexed citations

10.

Boormans, Joost L., Jens Voortman, Geert J.L.H. van Leenders, et al.. (2021). Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial. BMC Cancer. 21(1). 1161–1161. 7 indexed citations

11.

Kok, Iris C., Rudolf S.N. Fehrmann, Bert van der Vegt, et al.. (2020). Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology. 10. 761–761. 18 indexed citations

12.

Jansen, Femke, Birgit I. Lissenberg‐Witte, Jan Buter, et al.. (2020). The course of symptoms of anxiety and depression from time of diagnosis up to 2 years follow-up in head and neck cancer patients treated with primary (chemo)radiation. Oral Oncology. 102. 104576–104576. 30 indexed citations

13.

Buffart, Laurien M., Johannes A. Langendijk, Marije R. Vergeer, et al.. (2020). Health-related quality of life and overall survival: a prospective study in patients with head and neck cancer treated with radiotherapy. Quality of Life Research. 30(4). 1145–1153. 19 indexed citations

14.

Vorst, Maurice J. D. L. van der, et al.. (2019). Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer. 19(1). 1066–1066. 31 indexed citations

15.

Jansen, B.H.E., Maqsood Yaqub, Jens Voortman, et al.. (2019). Simplified Methods for Quantification of ¹⁸F-DCFPyL Uptake in Patients with Prostate Cancer. Journal of Nuclear Medicine. 60(12). 1730–1735. 27 indexed citations

16.

Cysouw, Matthijs C. F., G. Krämer, Dennis Heijtel, et al.. (2019). Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. EJNMMI Research. 9(1). 70–70. 8 indexed citations

17.

Poel, Dennis, et al.. (2018). Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Experimental & Molecular Medicine. 50(3). e454–e454. 58 indexed citations

18.

Rovithi, Maria, Richard J. Honeywell, Albert J. ten Tije, et al.. (2018). Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. Journal of Clinical Oncology. 37(5). 411–418. 13 indexed citations

19.

Voortman, Jens, Agnieszka Chęcińska, & Giuseppe Giaccone. (2007). The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Molecular Cancer. 6(1). 73–73. 20 indexed citations

20.

Voortman, Jens & Giuseppe Giaccone. (2006). Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 6(1). 129–129. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact